favicon

Alopecia Areata

Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata (March 16, 2020).

Recognition reinforces baricitinib’s potential to be the first FDA-approved medicine for individuals living with alopecia areata.

Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
0

Add a Comment

Your email address will not be published. Required fields are marked *

 

This site uses Akismet to reduce spam. Learn how your comment data is processed.